Novo Nordisk’s Raised Guidance Fuels Bull Case, but Pricing Pressure Persists

What happened

A Seeking Alpha article today reiterated a Buy rating on Novo Nordisk, arguing the market continues to underestimate the company’s long-term obesity franchise, especially with the Wegovy pill. Management recently raised 2026 guidance, now expecting adjusted sales and operating profit to decline at most 6%, a marked improvement from a prior -12% worst case, signaling better near-term demand. However, near-term headwinds such as declining gross margins, elevated capex, and the failed ziltivekimab trial remind investors that competitive and operational challenges persist. Oral Wegovy prescriptions remain robust at over 265,000 weekly U.S. scripts, but realized prices are still compressing top-line conversion. The stock at $47.3 trades at just 11.6x earnings, leaving room for upside if upcoming catalysts—including the September 2026 Capital Markets Day and a Q4 FDA decision on CagriSema—reinforce the thesis that volume can outrun price erosion.

Implication

For investors, the article reinforces that Novo’s depressed multiple overlooks oral Wegovy’s demand, yet the stock will remain under pressure unless gross-to-net trends improve. The guidance raise confirms management’s confidence, but declining margins suggest competitive intensity is still weighing on profitability. Near-term catalysts like the September CMD and CagriSema FDA decision could reshape sentiment if they signal better access economics or pipeline success. However, until U.S. obesity sales growth re-accelerates beyond mid-single digits with stable pricing, the stock may stay within the $44–$56 range outlined in the DeepValue report. Position sizing should consider the binary risk of CagriSema and the importance of Medicare Bridge uptake.

Thesis delta

The article does not materially shift the thesis; it reiterates existing bullish points without new data. It aligns with the DeepValue base case that oral Wegovy demand is strong but pricing remains the key risk. The investment thesis remains contingent on Q3 2026 results confirming volume growth can overtake price pressure.